IO Biotech Announces Participation in Upcoming Investor Conferences


NEW YORK, Nov. 11, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, off-the-shelf, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today announced that members of its senior management team will participate in the following upcoming investor conferences:

Read the original:
IO Biotech Announces Participation in Upcoming Investor Conferences

Related Posts